In this context, oncomiR-106b and oncomiR-93 are both up-regulated in GC and target the downstream E2F1 (E2F transcription factor 1) and p21 (cyclin-dependent kinase inhibitor 1A), thereby inhibiting the activity of TGF-β1 [26] and contributing to GC by enhancing cell proliferation. The gene discussed is CDKN1A; the disease is gastric cancer.